Oragenics, Inc. (OGEN)
USD 0.18
(0.57%)
USD 0.18
(0.57%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -20.9 Million USD | -45.02% |
| 2022 | -14.41 Million USD | 8.59% |
| 2021 | -15.77 Million USD | 40.8% |
| 2020 | -26.64 Million USD | -67.79% |
| 2019 | -15.87 Million USD | -58.87% |
| 2018 | -9.99 Million USD | -48.76% |
| 2017 | -6.71 Million USD | 21.35% |
| 2016 | -8.54 Million USD | 26.69% |
| 2015 | -11.65 Million USD | -100.33% |
| 2014 | -5.81 Million USD | 64.12% |
| 2013 | -16.21 Million USD | -30.39% |
| 2012 | -12.43 Million USD | -69.23% |
| 2011 | -7.34 Million USD | 7.04% |
| 2010 | -7.9 Million USD | -24.82% |
| 2009 | -6.33 Million USD | -4.67% |
| 2008 | -6.04 Million USD | -158.6% |
| 2007 | -2.33 Million USD | 21.02% |
| 2006 | -2.96 Million USD | 9.26% |
| 2005 | -3.26 Million USD | -4.46% |
| 2004 | -3.12 Million USD | -87.34% |
| 2003 | -1.66 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -2.3 Million USD | 6.26% |
| 2024 Q1 | -2.46 Million USD | 2.49% |
| 2023 Q3 | -2.09 Million USD | 32.64% |
| 2023 Q1 | -2.9 Million USD | -705.96% |
| 2023 Q2 | -3.1 Million USD | -7.04% |
| 2023 Q4 | -2.52 Million USD | -20.45% |
| 2023 FY | -10.66 Million USD | 25.99% |
| 2022 FY | -14.41 Million USD | 8.59% |
| 2022 Q3 | -3.95 Million USD | 2.31% |
| 2022 Q4 | -360.41 Thousand USD | 90.88% |
| 2022 Q1 | -6.05 Million USD | -163.11% |
| 2022 Q2 | -4.04 Million USD | 33.16% |
| 2021 Q3 | -4.39 Million USD | -14.5% |
| 2021 Q4 | -2.3 Million USD | 47.64% |
| 2021 Q1 | -5.23 Million USD | -15.13% |
| 2021 Q2 | -3.83 Million USD | 26.72% |
| 2021 FY | -15.77 Million USD | 40.8% |
| 2020 FY | -26.64 Million USD | -67.79% |
| 2020 Q2 | -12.35 Million USD | -136.1% |
| 2020 Q1 | -5.23 Million USD | -43.02% |
| 2020 Q4 | -4.54 Million USD | -0.9% |
| 2020 Q3 | -4.5 Million USD | 63.5% |
| 2019 Q4 | -3.65 Million USD | 6.69% |
| 2019 FY | -15.87 Million USD | -58.87% |
| 2019 Q3 | -3.92 Million USD | 20.07% |
| 2019 Q1 | -3.39 Million USD | -20.17% |
| 2019 Q2 | -4.9 Million USD | -44.51% |
| 2018 FY | -9.99 Million USD | -48.76% |
| 2018 Q2 | -2.28 Million USD | -7.63% |
| 2018 Q4 | -2.82 Million USD | -2.18% |
| 2018 Q3 | -2.76 Million USD | -21.05% |
| 2018 Q1 | -2.12 Million USD | -50.22% |
| 2017 Q2 | -1.39 Million USD | 29.73% |
| 2017 Q1 | -1.98 Million USD | 26.6% |
| 2017 Q4 | -1.41 Million USD | 26.5% |
| 2017 Q3 | -1.92 Million USD | -37.57% |
| 2017 FY | -6.71 Million USD | 21.35% |
| 2016 Q4 | -2.7 Million USD | -33.61% |
| 2016 FY | -8.54 Million USD | 26.69% |
| 2016 Q3 | -2.02 Million USD | -16.93% |
| 2016 Q2 | -1.73 Million USD | 16.0% |
| 2016 Q1 | -2.06 Million USD | 6.03% |
| 2015 Q3 | -1.82 Million USD | 71.1% |
| 2015 FY | -11.65 Million USD | -100.33% |
| 2015 Q4 | -2.19 Million USD | -20.03% |
| 2015 Q2 | -6.33 Million USD | -388.34% |
| 2015 Q1 | -1.29 Million USD | -5.37% |
| 2014 Q3 | -1.03 Million USD | 45.61% |
| 2014 FY | -5.81 Million USD | 64.12% |
| 2014 Q1 | -1.64 Million USD | 46.35% |
| 2014 Q2 | -1.9 Million USD | -15.38% |
| 2014 Q4 | -1.23 Million USD | -18.87% |
| 2013 FY | -16.21 Million USD | -30.39% |
| 2013 Q3 | -9.32 Million USD | -349.36% |
| 2013 Q1 | -1.73 Million USD | 12.68% |
| 2013 Q4 | -3.07 Million USD | 67.04% |
| 2013 Q2 | -2.07 Million USD | -19.53% |
| 2012 Q4 | -1.98 Million USD | 5.17% |
| 2012 Q1 | -1.47 Million USD | 18.54% |
| 2012 FY | -12.43 Million USD | -69.23% |
| 2012 Q2 | -6.86 Million USD | -364.45% |
| 2012 Q3 | -2.09 Million USD | 69.48% |
| 2011 Q1 | -1.51 Million USD | 33.37% |
| 2011 Q4 | -1.81 Million USD | -6.1% |
| 2011 Q2 | -2.3 Million USD | -52.07% |
| 2011 FY | -7.34 Million USD | 7.04% |
| 2011 Q3 | -1.71 Million USD | 25.75% |
| 2010 Q2 | -2 Million USD | -14.91% |
| 2010 FY | -7.9 Million USD | -24.82% |
| 2010 Q4 | -2.27 Million USD | -21.59% |
| 2010 Q1 | -1.74 Million USD | -33.98% |
| 2010 Q3 | -1.87 Million USD | 6.9% |
| 2009 Q4 | -1.3 Million USD | 10.56% |
| 2009 FY | -6.33 Million USD | -4.67% |
| 2009 Q1 | -1.98 Million USD | 33.62% |
| 2009 Q2 | -1.58 Million USD | 19.86% |
| 2009 Q3 | -1.45 Million USD | 8.06% |
| 2008 Q3 | -1.15 Million USD | -3.75% |
| 2008 Q1 | -801.09 Thousand USD | -15.85% |
| 2008 FY | -6.04 Million USD | -158.6% |
| 2008 Q4 | -2.98 Million USD | -158.69% |
| 2008 Q2 | -1.11 Million USD | -38.75% |
| 2007 Q2 | -596.29 Thousand USD | -8.22% |
| 2007 Q1 | -550.98 Thousand USD | 24.2% |
| 2007 Q4 | -691.51 Thousand USD | -39.49% |
| 2007 Q3 | -495.73 Thousand USD | 16.86% |
| 2007 FY | -2.33 Million USD | 21.02% |
| 2006 Q2 | -801.83 Thousand USD | 7.32% |
| 2006 Q4 | -726.9 Thousand USD | -27.99% |
| 2006 Q3 | -567.95 Thousand USD | 29.17% |
| 2006 FY | -2.96 Million USD | 9.26% |
| 2006 Q1 | -865.13 Thousand USD | -13.83% |
| 2005 Q3 | -750 Thousand USD | 14.28% |
| 2005 Q1 | 879.1 Thousand USD | 168.98% |
| 2005 FY | -3.26 Million USD | -4.46% |
| 2005 Q2 | -874.96 Thousand USD | -199.53% |
| 2005 Q4 | -760 Thousand USD | -1.33% |
| 2004 Q2 | -678.96 Thousand USD | -224.7% |
| 2004 Q1 | 544.46 Thousand USD | 186.53% |
| 2004 Q3 | -626.91 Thousand USD | 7.67% |
| 2004 Q4 | -1.27 Million USD | -103.28% |
| 2004 FY | -3.12 Million USD | -87.34% |
| 2003 Q2 | -432.44 Thousand USD | -108.0% |
| 2003 Q4 | -629.18 Thousand USD | -57.92% |
| 2003 FY | -1.66 Million USD | 0.0% |
| 2003 Q3 | -398.42 Thousand USD | 7.87% |
| 2003 Q1 | -207.89 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.91 Million USD | 34.5% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -119.635% |
| Armata Pharmaceuticals, Inc. | -40.89 Million USD | 48.875% |
| Actinium Pharmaceuticals, Inc. | -51.92 Million USD | 59.736% |
| Azitra, Inc. | -7.61 Million USD | -174.472% |
| Can-Fite BioPharma Ltd. | -8.19 Million USD | -155.093% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | -204.635% |
| Calidi Biotherapeutics, Inc. | -28.99 Million USD | 27.894% |
| CEL-SCI Corporation | -31.47 Million USD | 33.585% |
| iBio, Inc. | -16.63 Million USD | -25.676% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | 15.478% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | -3.58% |
| Matinas BioPharma Holdings, Inc. | -23.76 Million USD | 12.039% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | -48.78% |
| NovaBay Pharmaceuticals, Inc. | -5 Million USD | -317.847% |
| NanoViricides, Inc. | -8.51 Million USD | -145.475% |
| BiomX Inc. | -27.68 Million USD | 24.49% |
| BiomX Inc. | -27.68 Million USD | 24.49% |
| Protalix BioTherapeutics, Inc. | 10.46 Million USD | 299.856% |
| Palatin Technologies, Inc. | -22.49 Million USD | 7.073% |
| Scorpius Holdings, Inc. | -42.03 Million USD | 50.265% |
| Theriva Biologics, Inc. | -21.43 Million USD | 2.455% |